NASDAQ:ACCD - Accolade Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $60.45
  • Forecasted Upside: 39.10 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$43.46
▲ +0.4 (0.93%)

This chart shows the closing price for ACCD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Accolade Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACCD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACCD

Analyst Price Target is $60.45
▲ +39.10% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Accolade in the last 3 months. The average price target is $60.45, with a high forecast of $70.00 and a low forecast of $50.00. The average price target represents a 39.10% upside from the last price of $43.46.

This chart shows the closing price for ACCD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 contributing investment analysts is to buy stock in Accolade.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/2/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/17/2021Robert W. BairdUpgradeNeutral ➝ Outperform$58.00 ➝ $54.00Low
7/13/2021Robert W. BairdBoost Price TargetNeutral$54.00 ➝ $58.00Low
7/11/2021SVB LeerinkInitiated CoverageBuy$58.00Low
7/9/2021Stifel NicolausBoost Price TargetBuy$54.00 ➝ $64.00Low
7/9/2021Needham & Company LLCBoost Price TargetPositive ➝ Buy$59.00 ➝ $68.00Medium
7/7/2021Credit Suisse GroupBoost Price TargetOutperform$59.00 ➝ $70.00High
7/2/2021Morgan StanleyBoost Price TargetOverweight$60.00 ➝ $68.00Low
5/27/2021Robert W. BairdInitiated CoverageNeutral$54.00Medium
5/6/2021SVB LeerinkUpgradeMarket Perform ➝ OutperformHigh
4/27/2021SVB LeerinkReiterated RatingHoldMedium
4/15/2021Needham & Company LLCInitiated CoverageBuy$59.00Medium
4/6/2021Morgan StanleyBoost Price TargetOverweight$57.00 ➝ $60.00High
3/18/2021Canaccord GenuityBoost Price TargetBuy$59.00 ➝ $62.00High
3/11/2021The Goldman Sachs GroupInitiated CoverageBuyHigh
2/16/2021Piper SandlerBoost Price TargetOverweight$57.00 ➝ $60.00Low
1/15/2021BTIG ResearchBoost Price TargetPositive ➝ Buy$55.00 ➝ $60.00High
1/15/2021Robert W. BairdBoost Price TargetOutperform$50.00 ➝ $55.00High
1/15/2021SVB LeerinkBoost Price TargetMarket Perform$53.00 ➝ $56.00High
1/15/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform$45.00 ➝ $60.00High
1/8/2021Credit Suisse GroupBoost Price TargetNeutral ➝ Neutral$42.00 ➝ $45.00High
1/8/2021Robert W. BairdBoost Price TargetPositive ➝ Outperform$45.00 ➝ $50.00High
1/8/2021SVB LeerinkBoost Price TargetMarket Perform$44.00 ➝ $53.00High
1/8/2021Piper SandlerBoost Price TargetOverweight$55.00 ➝ $57.00High
1/6/2021BTIG ResearchInitiated CoverageBuy$55.00N/A
12/8/2020Canaccord GenuityInitiated CoverageBuy$59.00High
11/16/2020Stifel NicolausInitiated CoverageBuy$48.00High
10/16/2020Morgan StanleyBoost Price TargetOverweight$37.00 ➝ $48.00Medium
10/15/2020Bank of AmericaBoost Price TargetBuy$45.00 ➝ $51.00High
10/15/2020DA DavidsonBoost Price TargetPositive ➝ Buy$45.00 ➝ $50.00High
10/15/2020SVB LeerinkBoost Price TargetMarket Perform$40.00 ➝ $44.00Low
10/15/2020Robert W. BairdBoost Price TargetOutperform$40.00 ➝ $45.00Low
10/15/2020Piper SandlerBoost Price TargetOverweight$45.00 ➝ $55.00Low
10/8/2020Bank of AmericaBoost Price TargetBuy$42.50 ➝ $45.00Medium
9/22/2020DA DavidsonInitiated CoverageBuy$45.00High
8/14/2020Credit Suisse GroupBoost Price TargetNeutral$38.00 ➝ $40.00High
8/14/2020SVB LeerinkBoost Price TargetMarket Perform$34.00 ➝ $40.00High
7/27/2020Robert W. BairdInitiated CoverageOutperform$40.00High
7/27/2020SVB LeerinkInitiated CoverageOutperform$34.00High
7/27/2020Bank of AmericaInitiated CoverageBuy$37.00High
7/27/2020Piper SandlerInitiated CoverageOverweight$45.00High
7/27/2020The Goldman Sachs GroupInitiated CoverageBuy$39.00High
7/27/2020Credit Suisse GroupInitiated CoverageNeutral$38.00High
7/27/2020Morgan StanleyInitiated CoverageOverweight$37.00High
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 7 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
7/29/2021
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2021
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/27/2021

Current Sentiment

  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Accolade logo
Accolade, Inc. develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was founded in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.
Read More

Today's Range

Now: $43.46
Low: $42.10
High: $43.59

50 Day Range

MA: $46.21
Low: $41.30
High: $49.99

52 Week Range

Now: $43.46
Low: $32.87
High: $65.25

Volume

354,472 shs

Average Volume

735,705 shs

Market Capitalization

$2.87 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Accolade?

The following Wall Street sell-side analysts have issued research reports on Accolade in the last year: Bank of America Co., BTIG Research, Canaccord Genuity, Credit Suisse Group AG, DA Davidson, Morgan Stanley, Needham & Company LLC, Piper Sandler, Robert W. Baird, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for ACCD.

What is the current price target for Accolade?

11 Wall Street analysts have set twelve-month price targets for Accolade in the last year. Their average twelve-month price target is $60.45, suggesting a possible upside of 40.4%. Credit Suisse Group AG has the highest price target set, predicting ACCD will reach $70.00 in the next twelve months. DA Davidson has the lowest price target set, forecasting a price of $50.00 for Accolade in the next year.
View the latest price targets for ACCD.

What is the current consensus analyst rating for Accolade?

Accolade currently has 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACCD will outperform the market and that investors should add to their positions of Accolade.
View the latest ratings for ACCD.

What other companies compete with Accolade?

How do I contact Accolade's investor relations team?

Accolade's physical mailing address is 660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING PA, 19462. The company's listed phone number is 206-926-8100 and its investor relations email address is [email protected] The official website for Accolade is accolade.com.